About ZAVESCA®

An oral therapy that can be used alone

ZAVESCA® is indicated for the treatment of adults with mild to moderate type 1 Gaucher disease who cannot be treated with enzyme replacement therapy (ERT)1

Proven to deliver measurable benefits

Clinical studies have shown that ZAVESCA® provides important benefits for people with mild to moderate type 1 Gaucher disease*:

  • Reduced swelling of the liver and spleen
  • Increased amounts of hemoglobin and platelets

*Individual results may vary.

No blood test required for eligibility

The label does not require a blood test to determine your eligibility to take ZAVESCA®1

Frequently asked questions (FAQs)

How is ZAVESCA® different from enzyme replacement therapy?

For adults with type 1 Gaucher disease, there are two ways to decrease the accumulation of fatty substances in the body. One way is by substrate reduction therapy, like ZAVESCA®, where the production of fatty substances is limited or reduced.1 The other way is enzyme replacement therapy (ERT), where man-made enzymes are added to the body to help break down the fatty substances.2

Can ZAVESCA® be used to treat type 1 Gaucher disease that has been previously treated with ERT?

Yes. Studies with ZAVESCA® included people who had never been treated with ERT as well as people who had previously taken imiglucerase, a kind of ERT, but who had stopped at least 6 months prior to taking ZAVESCA®.1

Within 6 to 12 months, people treated with ZAVESCA® had improvements in 2 key areas1:

  • Significant mean percent reduction in the size of livers
  • Significant mean percent reduction in size of spleens

Your doctor will generally monitor these key areas in addition to other tests to see how you’re responding to treatment.

What should I tell my doctor before taking ZAVESCA®?

Before you take ZAVESCA® tell your doctor if you1:

  • have kidney problems
  • have any other medical conditions
  • are pregnant or plan to become pregnant. It is not known if ZAVESCA® will harm your unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if ZAVESCA® passes into your breast milk. Do not breastfeed during treatment with ZAVESCA®. Talk to your healthcare provider about the best way to feed your baby during treatment with ZAVESCA®

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ZAVESCA® may affect how other medicines work.1

How do I take ZAVESCA®? When should I take ZAVESCA®?

It’s important to take ZAVESCA® as prescribed by your doctor. The recommended dosage of ZAVESCA® is usually 1 pill (100 mg) taken 3 times each day.1 In some cases, your doctor may have you take less, due to side effects like tremors and diarrhea.1 Your doctor will determine the right dose for you. You should take ZAVESCA® at the same time each day. If you miss a dose of ZAVESCA®, skip that dose. Take the next ZAVESCA® capsule at the usual time.1 For example, if your prescription is for ZAVESCA® 3 times a day, then take it when you first wake up, in the early afternoon, and before going to bed (or as close to 8-hour intervals as possible).

Some people experience fewer gastrointestinal disturbances when taking ZAVESCA® without food or by changing their diet to avoid foods high in carbohydrates.1 Talk with your doctor about what works best for you.

Where can I get more help/information?

National Gaucher Foundation

www.gaucherdisease.org
1-800-504-3189

References:

  1. ZAVESCA® (miglustat) full Prescribing Information. Actelion Pharmaceuticals US, Inc.
  2. Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type 1 Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110(7):2296-2301.
Expand ISI +